undamentalytics Newsletter
Sign in

Cumberland Pharmaceuticals Inc (CPIX) stock

Add to watchlist

Add holding +

NASDAQ: CPIX Nasdaq Pharmaceuticals Next results ~November 3, 2026

C Fundamentals grade

Cumberland Pharmaceuticals Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$2.8

Cash-flow model

Base case. Range ~$2.1–$3.6 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Overvalued

The price is above our entire value range; our base value is 34% below it.

Price used: $4.22, November 2, 2026

Cumberland Pharmaceuticals Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds18 adding, 11 cuttingOf 10 active managers that changed their stake, 5 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Cumberland Pharmaceuticals files

Where Cumberland Pharmaceuticals stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $40m, down 5.2% on a year earlier, against growth of 2.1% a quarter earlier. That puts it 40 of 47 for growth among the pharmaceuticals companies we cover. Free-cash-flow margin fell to 1.7% from 16.7% a year earlier. Operating margin narrowed to -24.1% from -12.7%. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 1 of our 3 financial-health checks. Our cash-flow model value is $2.79 a share.

Source: 10-Q filed August 7, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 3, 2026 (estimated)

Cumberland Pharmaceuticals Inc's trailing-twelve-month revenue fell 5.2% year on year, with a free-cash-flow margin of 1.7%. Where it stands out: gross margin of 82.9% ranks 7 of 59 pharmaceuticals companies we cover.

Our discounted-cash-flow model values the business at ~$2.8 per share in the base case (~$2.1–$3.6 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 90.3% while net income fell 272.4%: a 182pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Results due soon. Results are expected around 3 November; the share price can move sharply on the day.
  • Priced above our value. The share price of $4.22 is 34% above our value per share of $3.
  • Revenue shrinking. Revenue fell 5.2% over the last 12 months.
  • Growth slowing. The growth rate is 7.2 points lower than a quarter earlier.
  • Loss-making. Operating margin is -24.1%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 11.4 points on a year ago.

Latest results: FY2026 Q2

Filed August 7, 2026
Earnings per share
-$0.00 against an average estimate of -$0.07: beat by 98.4%
Revenue
$9m, down 18.8% on a year earlier
Share reaction
+5.2% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500
Next report
November 3, 2026

Cumberland Pharmaceuticals' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-10.0%
  • 1 week-3.0%
  • 1 month-42.9%
  • This year+36.7%
  • 1 year+82.0%
  • 5 years+100.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$39.9M
Operating margin
-24.1%
Net margin
-27.4%
EPS (TTM, diluted)
$-0.74

Growth

Revenue growth
−5.2%
Change in growth rate
−7.2 pts
Share count change
+1.5%

Cash

Free cash flow (TTM)
$683,899
FCF margin
1.7%
Stock pay % of revenue
1.1%

Earnings

Last results
August 4, 2026
Next results (est.)
November 3, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Announcement
  2. Announcement
  3. Announcement
  4. Results
  5. Announcement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Cumberland Pharmaceuticals Inc valuation models and calculator

What the price is pricing in

The share price implies about 10.1% a year of cash-flow growth for five years.That is faster than the 2.1% a year revenue growth Cumberland Pharmaceuticals has delivered.

Read with care: free cash flow has swung sharply in the past year (often a one-off tax, legal or working-capital item), so the cash-flow base behind this reading may be unusually low or high.

  • Priced in10.1%
  • Last 12 months-5.2%
  • 3 years a year-0.6%
  • 5 years a year2.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($4.27, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Sell12-month view
12-month price target
~$2.8
Price used
$4.27close November 3, 2026
Implied change
▼ 35%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Cumberland Pharmaceuticals Inc's free cash flow after stock-based pay with after-tax interest added back ($2.3M, FY2026 Q2 TTM), growing 2% a year for five years and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$2.2–~$3.6 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Cumberland Pharmaceuticals Inc's free cash flow after stock-based pay ( $2.3M, FY2026 Q2 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Cumberland Pharmaceuticals Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.76 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$2.8 ~$2.1–$3.6 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$2.8 ~$2.1–$3.6 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Cumberland Pharmaceuticals Inc with Pharmaceuticals in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −20%
  • Revenue growth 5 points higher ▲ +26%
  • Free-cash-flow margin 1 point lower ▼ −34%
  • Last year's free-cash-flow margin change, if it persists ▼ −84%
  • Discount rate 1 point higher ▼ −11%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $2$3$4$6$7$10
8.5% $2$3$3$4$6$7
10% $2$2$3$3$4$6

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$4.08$4.26$5.71$4.68$3.99$2.29$3.62$1.74$1.39$1.84$3.09$4.22
Market value$70m$69m$91m$73m$61m$35m$54m$25m$20m$26m$46m$62m
+ Net debt (− = net cash)−$37m−$30m−$36m−$8m−$10m−$10m−$12m−$4m−$6m$2m−$6m−$4m
Enterprise value$33m$39m$55m$65m$52m$25m$42m$22m$14m$28m$40m$59m
Multiples
Price / sales 2.1x2.1x2.2x2.5x1.8x0.9x1.5x0.6x0.5x0.7x1.0x1.6x
Price / earnings 95.3x———————————
Price / free cash flow 12.2x157.9x—27.5x21.9x6.6x8.7x3.0x3.4x—9.5x91.2x
EV / EBITDA 9.9x40.3x————————29.3x—

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

57 /100

Moderate moat

How hard Cumberland Pharmaceuticals's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 4 / 20

    Cash operating profit has been a median 4.5% of total assets over 8 years.

  • Pricing power 19 / 20

    Gross margin has been a median 81.3%, moving by 3.3 percentage points (standard deviation) across 8 years.

  • Durability 10 / 20

    Operating margin has been a median -13.9%; its worst year was -29.3%.

  • Cash conversion 13 / 20

    Free cash flow was positive in 8 of 10 years, at a median 8.9% of revenue.

  • Discipline 17 / 20

    The diluted share count fell 1.7% over five years; stock-based pay has been a median 1.8% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (62 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 3, 2026, after the close.

Analysts' consensus

No analyst estimates are published for Cumberland Pharmaceuticals Inc: too few analysts cover it.

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2021 −$0.07 −$0.00 +98.4%
Mar 2021 −$0.07 $0.07 +200.0%
Dec 2020 −$0.01 $0.01 +200.0%
Sept 2020 −$0.07 $0.02 +128.6%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 4, 2026

No numeric guidance in Cumberland Pharmaceuticals Inc's latest earnings release (filed August 4, 2026). Some companies give their outlook only on the earnings call.

Positioning

Short interest
3.8%
of tradable shares
Days to cover
8.06
at average volume
Short interest, 1 month
+33%
to October 15, 2026
Held by institutions
17%
of shares
Held by insiders
41.6%
of shares
Employees
88
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +82.0%

$2.32 on October 31, 2025 to $4.22

ThenNowEffect
Revenue (last 12 months) $42m $40m −5.2%
P/S multiple 0.8x 1.6x +94.8%
Share count 15m 15m −1.5%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

Last 3 years +169.4%

$1.57 on November 3, 2023 to $4.22

ThenNowEffect
Revenue (last 12 months) $41m $40m −1.8%
P/S multiple 0.6x 1.6x +179.8%
Share count 15m 15m −1.9%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CPIX+58%−52%−20%+32%+68%+37%
Industry peers (median)−20%−49%−13%−2%+7%−14%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CPIX50%33%50%42%50%64%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CPIX−40%−61%−48%−53%−72%−53%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 87% from November 22, 2017 to November 22, 2024. Getting back needed a 651% gain, reached on August 3, 2026, 619 days after the low.

Price behaviour

52-week range
$1.47 – $8.97
From 52-week high
−53.0%
vs 50-day average
−40.2%
vs 200-day average
−12.2%
Volatility (1 year)
110%
Beta vs S&P 500
0.91

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±10.7%
After a week
4 up, 8 down
typical move ±12.9%
After a month
3 up, 9 down
typical move ±15.0%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +5.2% +1.6% +10.9% −9.2%
May 5, 2026 −3.5% +2.2% 0.0% +28.9%
March 3, 2026 −24.2% −0.2% −34.7% −36.0%
November 4, 2025 −15.6% −0.8% −27.5% −14.9%
August 5, 2025 −20.0% +0.3% −27.4% −8.7%
May 6, 2025 −1.1% −0.4% +24.4% +20.8%
March 4, 2025 +31.7% −0.1% +0.6% −16.7%
November 7, 2024 −0.8% +1.2% 0.0% +3.3%
August 6, 2024 +5.0% +0.2% −2.1% −7.1%
May 7, 2024 +9.2% +0.1% +2.6% −6.5%
March 5, 2024 −4.4% −0.5% −10.3% −12.3%
November 7, 2023 −8.1% +0.4% −14.7% −16.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Cumberland Pharmaceuticals Inc’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: rated Sell.

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Cumberland Pharmaceuticals Inc in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Cumberland Pharmaceuticals Inc
$36M $38M $40M $42M $44M $46M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $39.3M Revenue (TTM), FY23 Q4: $39.6M Revenue (TTM), FY24 Q1: $38.8M Revenue (TTM), FY24 Q2: $37.8M Revenue (TTM), FY24 Q3: $36.8M Revenue (TTM), FY24 Q4: $37.9M Revenue (TTM), FY25 Q1: $41.1M Revenue (TTM), FY25 Q2: $42.1M Revenue (TTM), FY25 Q3: $41.3M Revenue (TTM), FY25 Q4: $44.5M Revenue (TTM), FY26 Q1: $41.9M Revenue (TTM), FY26 Q2: $39.9M $39.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $39.3M
FY23 Q4 $39.6M
FY24 Q1 $38.8M
FY24 Q2 $37.8M
FY24 Q3 $36.8M
FY24 Q4 $37.9M
FY25 Q1 $41.1M
FY25 Q2 $42.1M
FY25 Q3 $41.3M
FY25 Q4 $44.5M
FY26 Q1 $41.9M
FY26 Q2 $39.9M
Revenue growth, TTM YoY Cumberland Pharmaceuticals Inc
-10% 0% 10% 20% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: -4.6% Revenue growth, TTM YoY, FY23 Q4: -5.9% Revenue growth, TTM YoY, FY24 Q1: -3.1% Revenue growth, TTM YoY, FY24 Q2: -7.0% Revenue growth, TTM YoY, FY24 Q3: -6.5% Revenue growth, TTM YoY, FY24 Q4: -4.3% Revenue growth, TTM YoY, FY25 Q1: 5.8% Revenue growth, TTM YoY, FY25 Q2: 11.3% Revenue growth, TTM YoY, FY25 Q3: 12.2% Revenue growth, TTM YoY, FY25 Q4: 17.6% Revenue growth, TTM YoY, FY26 Q1: 2.1% Revenue growth, TTM YoY, FY26 Q2: -5.2% -5.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 -4.6%
FY23 Q4 -5.9%
FY24 Q1 -3.1%
FY24 Q2 -7.0%
FY24 Q3 -6.5%
FY24 Q4 -4.3%
FY25 Q1 5.8%
FY25 Q2 11.3%
FY25 Q3 12.2%
FY25 Q4 17.6%
FY26 Q1 2.1%
FY26 Q2 -5.2%
Operating margin (TTM) Cumberland Pharmaceuticals Inc
-30% -20% -10% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -14.4% Operating margin (TTM), FY23 Q4: -15.6% Operating margin (TTM), FY24 Q1: -16.8% Operating margin (TTM), FY24 Q2: -20.0% Operating margin (TTM), FY24 Q3: -20.1% Operating margin (TTM), FY24 Q4: -17.0% Operating margin (TTM), FY25 Q1: -8.0% Operating margin (TTM), FY25 Q2: -12.7% Operating margin (TTM), FY25 Q3: -13.7% Operating margin (TTM), FY25 Q4: -11.6% Operating margin (TTM), FY26 Q1: -22.9% Operating margin (TTM), FY26 Q2: -24.1% -24.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -14.4%
FY23 Q4 -15.6%
FY24 Q1 -16.8%
FY24 Q2 -20.0%
FY24 Q3 -20.1%
FY24 Q4 -17.0%
FY25 Q1 -8.0%
FY25 Q2 -12.7%
FY25 Q3 -13.7%
FY25 Q4 -11.6%
FY26 Q1 -22.9%
FY26 Q2 -24.1%
FCF margin (TTM) Cumberland Pharmaceuticals Inc
-10% 0% 10% 20% 30% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 21.9% FCF margin (TTM), FY23 Q4: 14.7% FCF margin (TTM), FY24 Q1: 13.3% FCF margin (TTM), FY24 Q2: -2.3% FCF margin (TTM), FY24 Q3: -4.3% FCF margin (TTM), FY24 Q4: -1.8% FCF margin (TTM), FY25 Q1: 13.0% FCF margin (TTM), FY25 Q2: 16.7% FCF margin (TTM), FY25 Q3: 16.3% FCF margin (TTM), FY25 Q4: 10.9% FCF margin (TTM), FY26 Q1: 3.3% FCF margin (TTM), FY26 Q2: 1.7% 1.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 21.9%
FY23 Q4 14.7%
FY24 Q1 13.3%
FY24 Q2 -2.3%
FY24 Q3 -4.3%
FY24 Q4 -1.8%
FY25 Q1 13.0%
FY25 Q2 16.7%
FY25 Q3 16.3%
FY25 Q4 10.9%
FY26 Q1 3.3%
FY26 Q2 1.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 44 46 51 49 32 37 34 33 41 29 34 37 36 42 40 38 45 40
Gross profit — — — — — — — 27 34 23 27 29 27 33 33 31 38 —
EBITDA 7 7 11 10 −2 6 3 1 −1 −8 −5 −2 −3 −0 −5 −2 1 −5
Operating income 6 7 10 9 −4 4 1 −1 −4 −11 −9 −6 −8 −6 −10 −6 −3 −10
Net income 3 2 6 6 −2 2 1 −1 −8 −7 −4 −3 −4 −6 −6 −6 −3 −11
Diluted EPS $0.17 $0.12 $0.28 $0.30 −$0.11 $0.14 $0.04 −$0.06 −$0.50 −$0.45 −$0.23 −$0.22 −$0.24 −$0.38 −$0.44 −$0.46 −$0.19 −$0.74
Growth (year on year)
Revenue — +5.4% +11.5% −4.5% −34.4% +15.2% −9.2% −1.5% +24.6% −28.7% +17.2% +8.9% −3.9% +16.7% −5.9% −4.3% +17.6% −5.2%
EBITDA — +13.5% +45.6% −10.7% −125.7% — −39.5% −71.3% −248.7% — — — — — — — — —
Operating income — +12.6% +51.5% −10.5% −143.1% — −68.8% −228.9% — — — — — — — — — —
Net income — −20.5% +130.3% +3.3% −136.0% — −69.8% −229.2% — — — — — — — — — —
Diluted EPS — −29.4% +133.3% +7.1% −136.7% — −71.4% −250.0% — — — — — — — — — —
Margins
Gross margin — — — — — — — 82.0% 82.1% 79.5% 78.4% 76.9% 75.5% 78.3% 84.7% 82.6% 85.0% —
EBITDA margin 15.1% 16.3% 21.3% 19.9% −7.8% 15.0% 10.0% 2.9% −3.5% −27.9% −14.2% −4.4% −8.5% −0.9% −11.7% −4.0% 3.0% −13.8%
Operating margin 13.3% 14.2% 19.3% 18.1% −11.9% 9.6% 3.3% −4.3% −9.9% −38.1% −27.0% −17.0% −21.3% −13.6% −24.2% −17.0% −6.3% −24.1%
Net margin 7.1% 5.4% 11.1% 12.0% −6.6% 6.6% 2.2% −2.9% −19.4% −23.7% −10.3% −8.9% −9.7% −13.3% −15.9% −17.1% −6.4% −27.4%
Free-cash-flow margin −0.5% −0.5% 16.6% 13.7% 2.0% 17.7% 17.1% 1.3% −2.0% 9.1% 8.2% 14.1% 17.3% 19.9% 14.7% −1.8% 10.9% 1.7%
Cash flow
Cash from operations 0 0 9 7 1 7 6 1 −1 3 3 5 6 8 6 −1 5 1
Capital spending 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Free cash flow −0 −0 8 7 1 7 6 0 −1 3 3 5 6 8 6 −1 5 1
Stock-based pay — 1 1 1 1 1 1 1 1 1 1 1 1 0 0 0 0 0
Free cash flow after stock pay — −1 8 6 −0 6 5 −0 −2 1 1 4 5 8 5 −1 4 0
Balance sheet
Cash 79 66 71 54 41 40 38 35 45 28 28 25 27 20 18 18 11 4
Total debt 0 5 5 4 0 0 2 4 10 20 19 15 15 16 13 20 5 0
Net debt (negative = net cash) −79 −61 −66 −50 −41 −40 −37 −30 −36 −8 −10 −10 −12 −4 −6 2 −6 −4
Diluted shares 18m 21m 21m 20m 18m 18m 17m 16m 16m 16m 15m 15m 15m 15m 14m 14m 15m 15m
Returned to shareholders
Buybacks 27 5 4 8 5 4 5 3 4 3 3 2 1 1 1 1 0 0
Total returned 27 5 4 8 5 4 5 3 4 3 3 2 1 1 1 1 0 0

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 3 checks passed · June 30, 2026
What it owns · $63m
Short-term assets $34mLonger-term assets $29m
What it owes, and who funded it · $63m
Short-term liabilities $35mLonger-term liabilities $11mShareholders' equity $17m
  • Short-term assets cover short-term liabilities $34m of assets due within a year against $35m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $34m short-term assets against $11m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$10m against $309,204 of interest.

From Cumberland Pharmaceuticals Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q2 TTM
Buybacks (TTM)
$71,440
Returned to shareholders
10%
of free cash flow
Buybacks, last 3 fiscal years
$1.6M
Diluted share count
+1.5%
year over year
Total shareholder yield
0.1%
dividends 0.0% + buybacks 0.1% of market value
R&D spending
12.6%
of revenue
Days sales outstanding
123 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in pharmaceuticals
Last 12 months unless stated CPIX IMCC BGM SBFM BFRI SCLX Median
Revenue, last 12 months $40m $39m $38m $35m $46m $32m $276m
Revenue growth, last 12 months −5.2% −0.7% 51.1% −2.7% 17.8% −28.5% 9.9%
Revenue growth, 3-year average −0.6% — — 34.5% 16.7% −12.0% 5.5%
Revenue growth, latest quarter −18.8% — — −1.6% 32.9% −22.8% 6.5%
Gross margin 82.9% 17.7% 16.6% 30.3% — 55.5% 62.0%
Operating margin −24.1% −21.2% −33.2% −16.6% −14.2% <−999% −5.9%
Operating margin, 3-year average −19.0% — — −16.5% −36.6% −512.2% −7.4%
Net margin −27.4% −20.7% −52.6% −16.5% −13.8% <−999% −7.3%
Cash from operations / revenue 1.9% 8.6% −6.3% −15.1% −17.2% −54.1% 10.2%
Free-cash-flow margin 1.7% 8.6% −10.4% −15.2% −17.2% −70.7% 8.6%
Free-cash-flow margin, 3-year average 5.4% — — −25.5% −31.6% −2.8% 7.4%
Stock pay / revenue 1.1% 0.0% 27.0% — 2.4% 51.0% 3.6%
Change in share count 1.5% 71.3% >999% 55.7% — — 1.9%

Median of all 75 companies we cover in pharmaceuticals. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

75 pharmaceuticals companies
Measure Company Peer median Rank
Revenue growth Growth -5.2% 10.0% 59 of 74
Change in growth rate Growth -7.2pp -0.3pp 55 of 74
Gross margin Profitability 82.9% 59.8% 7 of 59
Operating margin Profitability -24.1% -5.9% 46 of 67
Net margin Profitability -27.4% -7.3% 54 of 75
Free-cash-flow margin Cash generation 1.7% 10.1% 46 of 74
Stock pay as % of revenue Cash generation 1.1% 3.6% 11 of 69
Change in share count Balance sheet 1.5% 1.5% 33 of 62
Days sales outstanding Balance sheet 123 days 72 days 47 of 59

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue YoY
Products $40.4M ▲ 10.6%
Product Sancuso $11.9M ▲ 32.2%
Product Kristalose $10.5M ▼ 31.2%
Product Vibativ $9.5M ▲ 32.5%
Product Caldolor $4.7M ▼ 6.0%
Manufactured Product Other $4.1M ▲ 210.1%
Product Other $4.1M ▲ 210.1%
Product Talicia $3.3M —
Product Acetadote $508,169 ▲ 174.4%
Product Redi Trex $11,391 ▼ 87.4%
Product Omeclamox Pak -$10,436 —
Product Vaprisol -$18,346 —

These categories overlap or exclude eliminations, so shares aren't shown.

From Cumberland Pharmaceuticals Inc's 10-K filed March 9, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$16M
Institutions reporting
32
Shares held vs prior quarter
▼ 10.6%
Positions opened / closed
8 / 4

Top buyers and sellers, Q2 2026: 18 institutions bought and 11 sold ; the biggest buyer was Citadel Advisors LLC (+57K shares) and the biggest seller Bridgeway Capital Management, LLC (−137K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Ikarian Capital, LLC $3.3M 503K 20.4% ▼ 9.0%
Renaissance Technologies LLC $3.1M 478K 19.4% ▲ 1.6%
Vanguard Capital Management LLC $2.5M 379K 15.4% ▲ 4.9%
Dimensional Fund Advisors LP $1.5M 233K 9.4% ▼ 15.6%
Boothbay Fund Management, LLC $729,285 113K 4.6% ▼ 11.9%
Geode Capital Management, LLC $702,616 108K 4.4% ▼ 5.1%
Perceptive Advisors LLC $628,443 97K 3.9% ▼ 50.8%
Citadel Advisors LLC $475,574 73K 3.0% ▲ 341.0%
Blackrock, Inc. $411,785 64K 2.6% ▲ 11.7%
Bank Of New York Mellon Corp $378,807 58K 2.4% 0.0%
Jane Street Group, LLC $367,682 57K 2.3% ▲ 288.5%
Vanguard Fiduciary Trust Co $355,810 55K 2.2% ▲ 20.4%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Cumberland Pharmaceuticals Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 3, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • March 3, 2026
  • November 4, 2025
  • August 5, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Cumberland Pharmaceuticals Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Cumberland Pharmaceuticals Inc in brief

What does Cumberland Pharmaceuticals Inc do?
Cumberland Pharmaceuticals Inc is a US-listed company in the pharmaceuticals industry. Its financial year ends in December.
What is Cumberland Pharmaceuticals Inc's stock ticker?
Cumberland Pharmaceuticals Inc trades under the ticker CPIX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Cumberland Pharmaceuticals Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Cumberland Pharmaceuticals Inc reported revenue of $39.9M, 5.2% lower than a year earlier, according to its SEC filings.
What is Cumberland Pharmaceuticals Inc's free cash flow?
Cumberland Pharmaceuticals Inc's free-cash-flow margin is 1.7% of revenue over the trailing twelve months, ranking 46 of the 74 pharmaceuticals companies we cover.
What is Cumberland Pharmaceuticals Inc's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Cumberland Pharmaceuticals Inc's free cash flow after stock-based pay gives ~$2.8 per share in the base case, and ~$2.1–$3.6 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Cumberland Pharmaceuticals Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Ikarian Capital, LLC, Renaissance Technologies LLC and Vanguard Capital Management LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Cumberland Pharmaceuticals Inc buying back stock, and does it pay a dividend?
Cumberland Pharmaceuticals Inc spent $71,440 on share repurchases over the trailing twelve months, and its diluted share count still rose 1.5% over the year.
What is Cumberland Pharmaceuticals Inc's market cap?
On November 2, 2026, Cumberland Pharmaceuticals Inc's market capitalisation was about $62.4M and net debt of -$3.9M. Market figures come from third-party market data and may be delayed.
Who are Cumberland Pharmaceuticals Inc's competitors?
In our Pharmaceuticals peer group, the companies closest to Cumberland Pharmaceuticals Inc are IM Cannabis Corp., BGM Group Ltd., Sunshine Biopharma Inc., Biofrontera Inc. and Scilex Holding Co. The side-by-side comparison below sets their revenue, margins and growth against Cumberland Pharmaceuticals Inc's.
When is Cumberland Pharmaceuticals Inc's next earnings date?
Around November 3, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Cumberland Pharmaceuticals Inc announces its own schedule.